home / stock / ckdxf / ckdxf quote
Last: | $0.29 |
---|---|
Change Percent: | 0.0% |
Open: | $0.29 |
Close: | $0.29 |
High: | $0.29 |
Low: | $0.29 |
Volume: | 130 |
Last Trade Date Time: | 11/14/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.29 | $0.29 | $0.29 | $0.29 | $0.29 | 130 | 11-14-2023 |
$0.42 | $0.41 | $0.42 | $0.42 | $0.41 | 30,000 | 06-01-2023 |
$0.82 | $0 | $0.82 | $0 | $0 | 6 | 03-06-2023 |
$0.82 | $0.82 | $0.82 | $0.82 | $0.82 | 5,000 | 01-24-2022 |
$1.09 | $1.09 | $1.09 | $1.09 | $1.09 | 3,400 | 04-26-2021 |
$1.2 | $1.2 | $1.2 | $1.2 | $1.2 | 2,000 | 02-25-2021 |
$1.52 | $1.52 | $1.52 | $1.52 | $1.52 | 5,000 | 01-21-2021 |
$1.38 | $1.38 | $1.38 | $1.38 | $1.38 | 1,000 | 12-30-2020 |
$1.6 | $1.6 | $1.6 | $1.6 | $1.6 | 23,800 | 06-29-2020 |
$ | $N/A | $2.43 | $N/A | $N/A | 0 | 02-12-2020 |
$ | $N/A | $2.43 | $N/A | $N/A | 0 | 02-11-2020 |
$ | $N/A | $2.43 | $N/A | $N/A | 0 | 02-10-2020 |
$ | $N/A | $2.43 | $N/A | $N/A | 0 | 02-07-2020 |
$ | $N/A | $2.43 | $N/A | $N/A | 0 | 02-06-2020 |
$ | $N/A | $2.43 | $N/A | $N/A | 0 | 02-05-2020 |
$ | $N/A | $2.43 | $N/A | $N/A | 0 | 02-04-2020 |
$ | $N/A | $2.43 | $N/A | $N/A | 0 | 02-03-2020 |
$ | $N/A | $2.43 | $N/A | $N/A | 0 | 01-31-2020 |
$ | $N/A | $2.43 | $N/A | $N/A | 0 | 01-30-2020 |
$ | $N/A | $2.43 | $N/A | $N/A | 0 | 01-29-2020 |
News, Short Squeeze, Breakout and More Instantly...
Opthea Ltd Company Name:
CKDXF Stock Symbol:
OTCMKTS Market:
MELBOURNE, Australia and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, includ...
MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, incl...
MELBOURNE, Australia and PRINCETON, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, incl...